Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

3(42.9%)

Phase 1

2(28.6%)

Phase 2

2(28.6%)

7Total

Phase 3(3)

Phase 1(2)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT00966914Phase 3Completed

Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin

Role: lead

NCT00039780Phase 3Completed

Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel

Role: lead

NCT00477282Phase 3Completed

Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer

Role: lead

NCT00062491Phase 2Completed

Study of Karenitecin (BNP1350) to Treat Malignant Melanoma

Role: lead

NCT00062478Phase 2Completed

Study of Karenitecin (BNP1350) in Patients With Brain Tumors

Role: lead

NCT00097903Phase 1Completed

Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer

Role: lead

NCT00358319Phase 1Terminated

Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma

Role: collaborator

All 7 trials loaded